Insulet Corp. logo
PODDInsulet Corp.

Cash Flow Statement

Operating, investing, and financing cash flow analysis

Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
619.300M113.800M183.300M125.700M196.500M63.800M147.700M98.500M86.800M
302.800M91.100M101.600M87.600M22.500M35.400M100.700M77.500M188.600M
101.100M26.200M30.600M22.000M22.300M21.700M21.500M21.300M19.200M
65.800M21.300M20.300M16.700M7.500M18.200M20.000M18.100M17.000M
Change in Accounts Receivable
1.968B544.700M516.900M462.200M444.500M402.300M365.500M375.600M348.600M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
2.100M-32.400M14.500M-33.100M53.100M-65.000M700K-13.100M-4.400M
Cash from Investing
-207.100M-27.800M-135.100M-21.000M-23.200M-12.300M-56.000M-26.700M-22.500M
0.000.000.000.000.000.000.000.000.00
Cash from Financing
Debt Repayment
-359.600M-300.000M0.00-29.500M-30.100M0.000.000.000.00
0.000.000.000.000.000.000.000.000.00
412.200M86.000M48.200M104.700M173.300M51.500M91.700M71.800M64.300M
Net Change in Cash
-802.700M-235.700M-41.300M-364.200M-161.500M329.700M50.800M81.600M69.800M

Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
569.300M430.300M145.700M119.000M-68.100M84.000M98.400M35.900M
247.100M418.300M206.300M4.600M16.800M6.800M11.600M3.292M
113.100M80.800M72.800M63.200M57.400M55.400M27.900M15.600M
62.700M69.300M48.300M40.900M34.400M35.900M28.700M37.500M
Change in Accounts Receivable
516.900M365.500M359.700M205.600M161.000M83.800M82.800M76.672M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-23.100M-17.000M-190.600M-2.500M-263.600M-63.400M-19.700M-52.800M
Cash from Investing
-191.600M-124.900M-75.600M-157.300M-122.700M-166.500M-170.900M-162.354M
0.000.00-3.000M-26.000M0.000.000.000.00
Cash from Financing
Debt Repayment
-59.600M0.000.000.000.000.000.000.00
0.000.000.000.000.000.000.000.00
377.700M305.400M70.100M-38.300M-190.800M-82.500M-72.500M-126.455M
Net Change in Cash
-237.300M249.200M14.500M-116.700M-115.600M708.300M99.800M-158.700M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy